References
- 1. www.accessdata.fda.gov/drugsatfda.../97/020639ap_Seroquel_apltr.pdf. (Access date November 22, 2015).
- 2. M. A. Kondo, K. Tajinda and C. Colantuoni, Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control, Transl. Psychiatry 3 (2013) 2-43; DOI: 10.1038/tp.2013.19.
- 3. J. Locklear, H. Svedsäter. C. Datto and J. Endicott, Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder, J. Affect. Disord. 149 (2013) 189-195; DOI: 10.1016/j.jad.2013.01.021.
- 4. C. Cecchic and P. Canonico, Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine, Riv. Psichiatr. 47 (2012) 30-39; DOI: 10.1708/1034.11289.
- 5. S. K. Srivastava, R. Verma, V. Chandra and S. P. Srivastava. Orally disintegrating tablets: A dosage form that extends the market exclusivity and patient protection, World J. Pharmacy Pharm. Sci. 3 (2014) 526-546.
- 6. http://reference.medscape.com/drug/seroquel-xr-quetiapine-342984#10 (Access date November 22, 2015).
- 7. L. V. Allen, N. G. Popovich and H. C. Ansel, Solid Dosage Forms and Solid Modified Release Delivery Systems, in Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott Williams & Wilkins, Philadelphia 2005.
- 8. G. M. Clarke and J. M. Newton, Short, comparative gastrointestinal transit of pellet systems of varying density, Int. J. Pharm. 114 (1995) 1-11; DOI: 10.1016/0378-5173(94)00200-O.
- 9. J. Collett and C. Moreton, Modified-Release per Oral Dosage Forms, in Pharmaceuticals: the Science of Dosage Form Design (Ed. M. E. Aulton), Churchill Livingstone, New York 2001, pp. 289-305.
- 10. M. K. Raval, R. V. Ramani and N. R. Sheth, Formulation and evaluation of sustained release entericcoated pellets of budesonide for intestinal delivery, Int. J. Pharm. Investig. 3 (2013) 203-211. DOI: 10.4103/2230-973X.121294.
- 11. M. H. Kumar, K. Samatha, A. Balaji and M. S. Shankar, Recent novel advancements in pellet formulation. A Review, Int. J. Pharm. Sci. Res. 4 (2013) 3803-3822; DOI: 10.13040/IJPSR.0975-8232.4 (10).3803-22.
- 12. Hoda Maher El Taher, Development of Pelletization Technology for the National Pharmaceutical Industry, Master thesis, Faculty of Pharmacy, Alexandria University.
- 13. S. El Gamal, V. Naggar and M. Sokar, Colon targeting of mebeverine HCl from pH-dependent tablet formulations, J. Am. Sci. 8 (2012) 632-638.
- 14. P. Dey and S. Maiti, Orodispersible tablets: A new trend in drug delivery, J. Nat. Sci. Biol. Med. 1 (2010) 2-5; DOI: 10.4103/0976-9668.71663.
- 15. S. Sherimeier and P. C. Schmidt, Fast dispersible ibuprofen tablets, Eur. J. Pharm. Sci. 15 (2002) 295-305; DOI: 10.1016/S0928-0987(02)00011-8.
- 16. C. Reitz and P. Kleinebudde, Solid lipid extrusion of sustained release dosage forms, Eur. J. Pharm. Biopharm. 67 (2007) 440-448; DOI: 10.1016/j.ejpb.2007.03.008.
- 17. C. M. Adeyeye and J. C. Price, Development and evaluation of sustained-release ibuprofen-wax microspheres. In vitro dissolution studies, Pharm. Res. 11 (1994) 575-579; DOI: 10.1023/A:1018931002991.
- 18. J. B. Schwartz, A. P. Simonelli and W. I. Higuchi, Drug release from wax matrices. I. Analysis of data with first-order kinetics and with the diffusion-controlled model, J. Pharm. Sci. 57 (1968) 274-277; DOI: 10.1002/jps.2600570206.
- 19. R. Senjković and I. Jalšenjak, Apparent diffusion coefficient of sodium phenobarbitone in ethylcellulose microcapsules: Effects of capsule size, J. Pharm. Pharmacol. 33 (1981) 279-282; DOI: 10.1111/ j.2042-7158.1981.tb13781.x.
- 20. J. Hamdani, A. J. Moes and K. Amighi, Physical and thermal characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets, Int. J. Pharm. 206 (2003) 47-57; DOI: 10.1016/S0378-5173(03)00229-1.
- 21. R. Bodmeier, Tableting of coated pellets, Eur. J. Pharm. Biopharm. 43 (1997) 1-8; DOI: 10.1016/S0939-6411(96)00028-8.
- 22. F. Al Husban, Y. Perrie and A. R. Mohamed, Formulation of multiparticulate systems as lyophilised orally disintegrating tablets, Eur. J. Pharm. Biopharm. 79 (2011) 627-634; DOI: 10.1016/j.ejpb.2011.05.014.
- 23. F. Lai, E. Pini, F. Corrias, J. Perricci, M. Manconi, A. M. Fadda and C. Sinico, Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freezedrying, Int. J. Pharm. 467 (2014) 27-33; DOI: 10.1016/j.ijpharm.2014.03.047.
- 24. http://www.brenntagspecialties.com/en/downloads/Products/Multi_Market_Principals/Ashland/PVP_-_PVP_VA/PVP_Brochure.pdf (access date November 22, 2015).
- 25. A. K. Nayak and K. Manna, Current developments in orally disintegrating tablet technology, J. Pharm. Educ. Res. 2 (2011) 1-10.
- 26. C. Michon, B. Cuvelier, B. Launay, A. Parker and G. Takerkart. Study of the compatibility/incompatibility of gelatin/iota-carrageenan/gelatin/water mixtures, Carbohydr. Polym. 28 (1995) 333-336; DOI: 10.1016/0144-8617(95)00096-8.
- 27. R. Chandrasekhar, Z. Hassan, A. M. Smith and F. Al Husban, The role of formulation excipients in the development of lyophilized fast-disintegrating tablets, Eur. J. Pharm. Biopharm. 72 (2009) 119-129; DOI: 10.1016/j.ejpb.2008.11.011.
- 28. F. Al Husban, Y. Perrie and A. R. Mohammed, Preparation, optimisation and characterization of lyophilized rapid disintegrating tablets based on gelatin and saccharide, Curr. Drug Deliv. 7 (2010) 65-75; DOI: 10.2174/156720110790396427.
- 29. X. Tang and M. J. Pikal, Design of freeze-drying processes for pharmaceuticals: practical advice, Pharmaceut. Res. 21 (2004) 191-200; DOI: 10.1023/B:PHAM.0000016234.73023.75.
- 30. Guidance for Industry: Orally Disintegrating Tablets, FDA CDER Data Standards Manual, 2008.